Abstract: Example embodiments described herein are directed towards dynamic state estimation of an operating state of a generator in a power system. Such estimation is performed for an individual generator in real time with improved accuracy and without the use of Global Position System (GPS) synchronization.

Abstract: A power transmission network including a single-phase or multi-phase AC electrical system, a converter including an AC terminal, a point of common coupling, a phase reactance connecting the common coupling to each AC terminal, and a transmission medium to interconnect the common coupling and the electrical system. The network includes a controller to: process the voltage and current at the common coupling to compute a state vector; derive a converter demand by combining the state vector with control parameters, including the capacitance of the power transmission medium presented at the common coupling and the impedance of the phase reactance; and operate the converter according to demand controlling the voltage at each terminal and/or the common coupling to inhibit any perturbation in the converter voltage from a target converter voltage or range resulting from the interaction between the capacitance of the power transmission medium and the impedance of the phase reactance.

Abstract: A power transmission network including a single-phase or multi-phase AC electrical system, a converter including an AC terminal, a point of common coupling, a phase reactance connecting the common coupling to each AC terminal, and a transmission medium to interconnect the common coupling and the electrical system. The network includes a controller to: process the voltage and current at the common coupling to compute a state vector; derive a converter demand by combining the state vector with control parameters, including the capacitance of the power transmission medium presented at the common coupling and the impedance of the phase reactance; and operate the converter according to demand controlling the voltage at each terminal and/or the common coupling to inhibit any perturbation in the converter voltage from a target converter voltage or range resulting from the interaction between the capacitance of the power transmission medium and the impedance of the phase reactance.

Abstract: A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of Piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination.

Abstract: This invention relates to use of betel leaf extract to induce IFN? from human peripheral blood mononuclear cells and as a Th1 type immuno modulator, wherein the said method comprises the steps of, preparing water extract of betel leaf, preparation of human peripheral blood mononuclear cells, incubation of hPBMC with betel leaf extract for a period of 18–48 hours, extraction of RNA for cytokine specific RT-PCR or for flow cytometry for the detection of intracellular cytokine protein, subjecting RNA for RT-PCR to obtain PCR products using IFN? specific known primers, and enhancement of IFN? as reflected by IFN? specific band.

Abstract: This invention relates to use of betel leaf extract to induce IFN? from human peripheral blood mononuclear cells and as a Th1 type immuno modulator, wherein the said method comprises the steps of, preparing water extract of betel leaf, preparation of human peripheral blood mononuclear cells, incubation of hPBMC with betel leaf extract for a period of 18-48 hours, extraction of RNA for cytokine specific RT-PCR or for flow cytometry for the detection of intracellular cytokine protein, subjecting RNA for RT-PCR to obtain PCR products using IFN? specific known primers, and enhancement of IFN? as reflected by IFN? specific band.

Abstract: The present invention relates to a method of preventing and/or treating diabetes type 2, also, it relates to a method of augmenting Glut4 phosphorylation and Glut4 translocation to a target cell membrane to enhance insulin signal in a signal transduction pathway; further, it relates to a simplified and inexpensive process of obtaining extract and thereafter selectively, its active n-butanol fraction and active molecule Lupinoside PA (LPA4), useful in preventing and/or treating diabetes type 2; and lastly, a pharmaceutical composition thereof.

Abstract: The present invention relates to a method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract of piper betel by HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

Abstract: This invention relates to method of treating visceral leishmaniasis or kala-azar by administering effective amount of betel leaf extract or lyophilized extract together with or associated with an additive and a composition comprising betel leaf extract with a pharmaceutically acceptable additive.

Abstract: This invention relates to use of betel leaf extract to induce IFN&ggr; from human peripheral blood mononuclear cells and as a Th1 type immuno modulator, wherein the said method comprises the steps of, preparing water extract of betel leaf, preparation of human peripheral blood mononuclear cells, incubation of hPBMC with betel leaf extract for a period of 18-48 hours, extraction of RNA for cytokine specific RT-PCR or for flow cytometry for the detection of intracellular cytokine protein, subjecting RNA for RT-PCR to obtain PCR products using IFN&ggr; specific known primers, and enhancement of IFN&ggr; as reflected by IFN&ggr; specific band.

Abstract: This invention relates to use of betel leaf extract to induce IFN&ggr; from human peripheral blood mononuclear cells and as a Th1 type immuno modulator, wherein the said method comprises the steps of, preparing water extract of betel leaf, preparation of human peripheral blood mononuclear cells, incubation of hPBMC with betel leaf extract for a period of 18-48 hours, extraction of RNA for cytokine specific RT-PCR or for flow cytometry for the detection of intracellular cytokine protein, subjecting RNA for RT-PCR to obtain PCR products using IFN&ggr; specific known primers, and enhancement of IFN&ggr; as reflected by IFN&ggr; specific band.

Abstract: This invention relates to method of treating visceral leishmaniasis or kala-azar by administering effective amount of betel leaf extract or lyophilized extract together with or associated with an additive and a composition comprising betel leaf extract with a pharmaceutically acceptable additive.

Abstract: This invention relates to use of betel leaf extract to induce IFN&ggr; from human peripheral blood mononuclear cells and as a Th1 type immuno modulator, wherein the said method comprises the steps of, preparing water extract of betel leaf, preparation of human peripheral blood mononuclear cells, incubation of hPBMC with betel leaf extract for a period of 18-48 hours, extraction of RNA for cytokine specific RT-PCR or for flow cytometry for the detection of intracellular cytokine protein, subjecting RNA for RT-PCR to obtain PCR products using IFN&ggr; specific known primers, and enhancement of IFN&ggr; as reflected by IFN&ggr; specific band.

Abstract: This invention relates to method of treating visceral leishmaniasis or kala-azar by administering effective amount of betel leaf extract or lyophilized extract together with or associated with an additive and a composition comprising betel leaf extract with a pharmaceutically acceptable additive.

Abstract: This invention relates to anti-monocytic activity of betel leaf extracts and this anti monocytic activity of betel leaf extracts suggest its use to treat myeloid leukemia in animal and human beings.